Medindia LOGIN REGISTER
Medindia
Advertisement

Genome Sequencing Technology Provides Insight into Causes of Pneumococcal Disease

by Bidita Debnath on May 9, 2013 at 10:43 AM
 Genome Sequencing Technology Provides Insight into Causes of Pneumococcal Disease

For the first time, researchers used genome sequencing technology to track the changes in a bacterial population following the introduction of a vaccine.

The study was led by researchers from Harvard School of Public Health (HSPH) and the Wellcome Trust Sanger Institute in the UK.

Advertisement

The study follows how the population of pneumococcal bacteria changed following the introduction of the 'Prevnar' conjugate polysaccharide vaccine, which substantially reduced rates of pneumococcal disease across the U.S. The work demonstrates that the technology could be used in the future to monitor the effectiveness of vaccination or antibiotic use against different species of bacterial pathogens, and for characterizing new and emerging threats.

The study appears online May 5, 2013 in Nature Genetics.

"This gives an unprecedented insight into the bacteria living and transmitting among us," said co-author William Hanage, associate professor of epidemiology at HSPH. "We can characterize these bugs to an almost unimaginable degree of detail, and in so doing understand better what helps them survive even in the presence of an effective vaccine."
Advertisement

Pneumococcal disease is caused by a type of bacteria called Streptococcus pneumoniae, which is present in many people's noses and throats and is spread by coughing, sneezing, or other contact with respiratory secretions. The circumstances that cause it to become pathogenic are not fully understood. Rates of pneumococcal disease—an infection that can lead to pneumonia, meningitis, and other illnesses—dropped in young children following the introduction of a vaccine in 2000. However, strains of the bacteria that are not targeted by the vaccine rapidly increased and drug resistance appears to be on the rise.

The research, led by HSPH co-senior authors Hanage; Marc Lipsitch, professor of epidemiology; and Stephen Bentley, senior scientist at the Wellcome Trust Sanger Institute, aimed to better understand the bacterial population's response to vaccination. Whole genome sequencing—which reveals the DNA code for each bacterial strain to an unprecedented level of detail—was used to study a sample of 616 pneumococci collected in Massachusetts communities from 2001 to 2007.

This study confirmed that the parts of the bacterial population targeted by the vaccine have almost disappeared, and, surprisingly, revealed that they have been replaced by pre-existing rare types of bacteria. The genetic composition of the new population is very similar to the original one, except for a few genes that were directly affected by the vaccine. This small genetic alteration appears to be responsible for the large reduction in the rates of pneumococcal disease.

"The widespread use of whole genome sequencing will allow better surveillance of bacterial populations — even those that are genetically diverse — and improve understanding of their evolution," said Lipsitch. "In this study, we were even able to see how quickly these bacteria transmit between different regions within Massachusetts and identify genes associated with bacteria in children of different ages."

"In the future, we will be able to monitor evolutionary changes in real-time. If we can more quickly and precisely trace the emergence of disease-causing bacteria, we may be able to better target interventions to limit the burden of disease," said Bentley.

Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Research News

South Korea's 2050 Forecast: Negative Growth Amid Low Fertility
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
New Immunotherapy for Psoriasis & Vitiligo
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
2050 Forecast: 1.06 Billion Individuals to Face 'Other' Musculoskeletal Disorders
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Gene Therapies Can Disrupt Gaucher Disease Drug Market
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
NASH Cases Expected to Hit 26.55 Million in 7MM by 2032
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Genome Sequencing Technology Provides Insight into Causes of Pneumococcal Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests